UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...
A new hand-held scanner can generate highly detailed 3D photoacoustic images in just seconds, paving the way for their use in a clinical setting for the first time and offering the potential for ...
Sep. 5, 2024 — Clinical studies have shown that periodontal disease with Aggregatibacter actinomycetemcomitans can exacerbate symptoms of rheumatoid arthritis (RA), but the molecular mechanisms ...
Symptoms and signs of thromboangiitis obliterans (TAO) include superficial thrombophlebitis, Raynaud phenomenon, and distal extremity ischemia (foot or calf claudication or both ... factor and ...